Reinventing the discovery, development, and commercialization of new medicines
We develop transformative medicines and technologies by building agile, focused companies called Vants.
subsidiary companies built
successful Phase 3 trials of 9 total
Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.
We employ technology across discovery, development, and commercialization.
Our CEO, Matt Gline, shares Roivant's progress and growth as VTAMA continues its positive impact on psoriasis patients, and Immunovant shares a new promising compound, IMVT-1402.
Learn more about our work
Sign up for our latest announcements and upcoming presentations
Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.